Related Experiment Video
Updated: Jun 23, 2025

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
Published on: June 27, 2020
FLI1 is associated with regulation of DNA methylation and megakaryocytic differentiation in FPDMM caused by a RUNX1
Yuki Tanaka1, Yuri Nakanishi1, Erina Furuhata1
1Laboratory for Cellular Function Conversion Technology, RIKEN Center for Integrative Medical Sciences (IMS), RIKEN Yokohama Campus, 1-7-22 Suehiro-Cho, Tsurumi-Ku, Yokohama City, Kanagawa, 230-0045, Japan.
Abstract:
Familial platelet disorder with associated myeloid malignancies (FPDMM) is an autosomal dominant disease caused by heterozygous germline mutations in RUNX1. It is characterized by thrombocytopenia, platelet dysfunction, and a predisposition to hematological malignancies. Although FPDMM is a precursor for diseases involving abnormal DNA methylation, the DNA methylation status in FPDMM remains unknown, largely due to a lack of animal models and challenges in obtaining patient-derived samples. Here, using genome editing techniques, we established two lines of human induced pluripotent stem cells (iPSCs) with different FPDMM-mimicking heterozygous RUNX1 mutations. These iPSCs showed defective differentiation of hematopoietic progenitor cells (HPCs) and megakaryocytes (Mks), consistent with FPDMM. The FPDMM-mimicking HPCs showed DNA methylation patterns distinct from those of wild-type HPCs, with hypermethylated regions showing the enrichment of ETS transcription factor (TF) motifs. We found that the expression of FLI1, an ETS family member, was significantly downregulated in FPDMM-mimicking HPCs with a RUNX1 transactivation domain (TAD) mutation. We demonstrated that FLI1 promoted binding-site-directed DNA demethylation, and that overexpression of FLI1 restored their megakaryocytic differentiation efficiency and hypermethylation status. These findings suggest that FLI1 plays a crucial role in regulating DNA methylation and correcting defective megakaryocytic differentiation in FPDMM-mimicking HPCs with a RUNX1 TAD mutation.
Insights
Familial platelet disorder with associated myeloid malignancies (FPDMM) involves RUNX1 mutations affecting blood cell development. This study reveals FLI1
Area of Science:
- Hematology
- Genetics
- Epigenetics
Background:
- Familial platelet disorder with associated myeloid malignancies (FPDMM) is an inherited condition linked to RUNX1 mutations.
- FPDMM patients exhibit low platelet counts, impaired platelet function, and increased risk of blood cancers.
- The DNA methylation status in FPDMM is largely unknown due to limited research models.
Purpose of the Study:
- To investigate the DNA methylation patterns in FPDMM using patient-derived cellular models.
- To explore the role of RUNX1 mutations and their impact on hematopoietic differentiation and DNA methylation.
- To identify potential therapeutic targets for FPDMM.
Main Methods:
- Generated human induced pluripotent stem cells (iPSCs) with RUNX1 mutations mimicking FPDMM.
- Analyzed hematopoietic progenitor cell (HPC) and megakaryocyte (Mk) differentiation from these iPSCs.
- Performed genome-wide DNA methylation analysis and transcription factor motif enrichment analysis.
- Assessed the role of FLI1 in DNA methylation and megakaryopoiesis.
Main Results:
- FPDMM-mimicking iPSCs showed impaired HPC and Mk differentiation.
- Distinct DNA methylation patterns were observed in FPDMM-mimicking HPCs, with hypermethylation enriched for ETS TF motifs.
- RUNX1 mutations, particularly in the transactivation domain (TAD), led to decreased FLI1 expression.
- FLI1 overexpression corrected megakaryocytic differentiation defects and normalized DNA methylation.
Conclusions:
- FLI1 plays a critical role in regulating DNA methylation and megakaryocytic differentiation in FPDMM.
- Restoring FLI1 function may be a therapeutic strategy for FPDMM with RUNX1 TAD mutations.
- This study provides novel insights into the epigenetic mechanisms underlying FPDMM.
Related Concept Videos
Epigenetic Regulation
Master Transcription Regulators
Abnormal Proliferation
Regulation of Angiogenesis and Blood Supply
Negative Regulator Molecules

